Senicapoc is primarily investigated for its potential therapeutic applications in treating sickle cell disease. It works by inhibiting the Gardos channel, a potassium channel in red blood cells, which helps reduce cell dehydration and hemolysis, thereby improving the overall health and lifespan of red blood cells in patients. This mechanism offers a promising approach to alleviate the symptoms and complications associated with sickle cell disease, such as anemia and vaso-occlusive crises. Additionally, research has explored its potential use in other conditions involving abnormal red blood cell physiology, though these applications are still in the experimental stages.